We are conducting a new Study for those living with Immune Thrombocytopenia (ITP) and / or Paroxysmal Nocturnal Hemoglobinuria (PNH). The purpose of this research is to gain a deeper understanding of your experiences and journey with this condition. The method of this study will be:
1. 60 Minute Web Assisted Discussion
Who are we looking for?
- 11 participants based within the UK who have been diagnosed either Immune Thrombocyto-penia (ITP) and / or Paroxysmal Nocturnal Hemoglobinuria (PNH).
Why should I take part?
- As a thank you for your time, we will offer you £50.00 which is payable as BACS, Cheque or Ama-zon Voucher.
By sharing with us your experiences, needs and wishes you have a real opportunity to influence healthcare decisions and help guide development of patient support and information materials. All answers provided are to be from your own personal experience and will only be used for in-ternal analysis. These will not be published in any external documents, stimulus or communica-tions.
A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia (ADVANCE SC+)
argenx BVBA is conducting a phase 3, multicentre, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of efgartigimod (ARGX 113), PH20 administered subcutaneously. This is a specially formulated antibody depletion therapy which is a human IgG Fc fragment that targets and binds to the neonatal Fc receptor (FcRn) to increase IgG clearance and block IgG recycling in the body. IgG antibodies accelerate platelet clearance and destruction, and also interfere with proper platelet production. Eligibility is restricted to adult patients 18 years of age or older who have persistent or chronic ITP and a platelet count lower than 30 x 109/L.